Sogroya Side Effects
Generic name: somapacitan-beco
Medically reviewed by Drugs.com. Last updated on Jul 16, 2024.
Note: This document provides detailed information about Sogroya Side Effects associated with somapacitan-beco. Some dosage forms listed on this page may not apply specifically to the brand name Sogroya.
Applies to somapacitan-beco: subcutaneous solution.
Serious side effects of Sogroya
Along with its needed effects, somapacitan-beco (the active ingredient contained in Sogroya) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking somapacitan-beco:
More common side effects
- bloating
- blurred vision
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in ability to see colors, especially blue or yellow
- chills
- constipation
- cough
- darkened urine
- darkening of the skin
- depressed mood
- diarrhea
- difficulty swallowing
- dizziness
- dry mouth
- dry skin and hair
- fainting
- fast heartbeat
- feeling cold
- fever
- flushed, dry skin
- fruit-like breath odor
- hair loss
- headache
- hives, itching, skin rash
- hoarseness or husky voice
- increased hunger
- increased thirst
- increased urination
- indigestion
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- loss of appetite
- loss of consciousness
- loss of fat or tissue weakness in the skin area at the injection site
- mental depression
- muscle cramps and stiffness
- nausea
- nervousness
- pains in the stomach, side, or abdomen, possibly radiating to the back
- pale skin
- persistent non-healing sore
- pink growth
- pounding in the ears
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- reddish patch or irritated area
- shiny bump
- slow or fast heartbeat
- stomach pain
- sweating
- swelling
- thickening of the skin
- tightness in the chest
- trouble breathing
- unexplained weight loss
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
- weight gain
- white, yellow or waxy scar-like area
- yellow eyes or skin
Other side effects of Sogroya
Some side effects of somapacitan-beco may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- acid or sour stomach
- back pain
- belching
- difficulty in moving
- heartburn
- muscle pain or stiffness
- pain in the joints
- stomach discomfort or upset
- trouble sleeping
For healthcare professionals
Applies to somapacitan-beco: subcutaneous solution.
General adverse events
In pediatric patients with growth hormone deficiency (GHD): Common adverse reactions occurring in 5% or more of patients receiving this drug include nasopharyngitis, headache, fever, extremity pain, and injection site reactions.
In adult patients with GHD: Adverse reactions occurring in over 2% of patients treated with this drug comprise back pain, joint pain, indigestion, sleep disturbances, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, high blood pressure, elevated blood creatine phosphokinase levels, weight gain, and anemia.[Ref]
Cardiovascular
- Common (1% to 10%): Hypertension[Ref]
Dermatologic
- Common (1% to 10%): Rash, urticaria
- Uncommon (0.1% to 1%): Lipohypertrophy, pruritus[Ref]
Endocrine
- Common (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism[Ref]
Gastrointestinal
- Common (1% to 10%): Dyspepsia, nausea/vomiting, diarrhea, gastroenteritis
- Frequency not reported: Pancreatitis[Ref]
Nausea/vomiting included vomiting (4.5%) and nausea (1.5%); Diarrhea included diarrhea (2.3%), gastroenteritis viral (1.5%), and gastrointestinal viral infection (0.8%).[Ref]
Hematologic
- Common (1% to 10%): Anemia[Ref]
Hypersensitivity
- Frequency not reported: Severe hypersensitivity[Ref]
Local
- Common (1% to 10%): Injection site reaction
- Frequency not reported: Lipohypertrophy, lipoatrophy[Ref]
Injection site reaction included injection site bruising (1.5%), injection site pain (1.5%), injection site hematoma (1.5%), injection site reaction (0.8%), and injection site swelling (0.8%).[Ref]
Metabolic
- Very common (10% or more): Elevated phosphate (17.5%)
- Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased, hyperglycemia
- Frequency not reported: Glucose intolerance, diabetes mellitus, fluid retention[Ref]
Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.[Ref]
Musculoskeletal
- Very common (10% or more): Back pain (10%)
- Common (1% to 10%): Arthralgia, myalgia, muscle stiffness
- Uncommon (0.1% to 1%): Joint stiffness[Ref]
Nervous system
- Very common (10% or more): Headache (12.1%)
- Common (1% to 10%): Sleep disorder, dizziness, paresthesia
- Uncommon (0.1% to 1%): Carpal tunnel syndrome
- Frequency not reported: Intracranial hypertension[Ref]
Oncologic
- Frequency not reported: Neoplasms[Ref]
Other
- Common (1% to 10%): Peripheral edema, pyrexia, fatigue, asthenia, influenza
- Frequency not reported: Increased mortality in patients with acute critical illness[Ref]
Pyrexia included pyrexia (8.3%) and hyperthermia (0.8%); pain in extremity included pain in extremity (9.1%) and growing pains (0.8%).[Ref]
Respiratory
- Very common (10% or more): Nasopharyngitis (16.7%)
- Common (1% to 10%): Tonsillitis, bronchitis, upper respiratory tract infection[Ref]
Nasopharyngitis included nasopharyngitis (11.4%), rhinitis (3.8%), pharyngitis streptococcal (0.8%), acute sinusitis (0.8%), nasal congestion (0.8%), pharyngitis (0.8%), and sinusitis (0.8%).[Ref]
References
1. (2022) "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Pty Ltd, Sogroya PI v2.0
2. (2020) "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc
More about Sogroya (somapacitan-beco)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: growth hormones
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Sogroya side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.